摘要
目的分析神经保护剂依达拉奉在急性脑梗死治疗中的应用效果。方法抽取2021年5月至2021年12月南阳市第一人民医院收治的急性脑梗死患者160例,按照随机双盲的原则将其分为常规组和神经保护剂组,每组80例。常规组给予纤溶酶溶栓治疗,神经保护剂组在常规组治疗的基础上给予依达拉奉右坎醇注射液,持续用药14 d后,比较两组患者临床疗效、神经功能缺损情况、生活能力评分及不良反应发生率;比较两组血流动力学指标以及纤维蛋白原含量。结果神经保护剂组临床总有效率(93.75%,75/80)高于常规组(78.75%,63/80),P<0.05。治疗后,两组患者美国国立卫生研究院卒中量表(NIHSS)评分均较治疗前降低,日常生活能力量表(ADL)评分均较治疗前升高,且神经保护剂组NIHSS和ADL评分的改善效果优于常规组,差异有统计学意义(P<0.05)。神经保护剂组患者的红细胞压积、全血高切黏度、血浆黏度及纤维蛋白原含量均低于常规组(P均<0.05)。神经保护剂组患者不良反应发生率(7.50%,6/80)低于常规组(18.75%,15/80),P<0.05。结论依达拉奉治疗急性脑梗死可以有效改善患者的神经功能缺损情况、生活质量和血流动力学指标,临床效果确切,安全性较高。
Objective To analyze the clinical efficacy of the neuroprotective agent edaravone on patients with acute cerebral infarction.Methods A total of 160 patients with acute cerebral infarction admitted to Nanyang First People’s Hospital from May 2021 to December 2021 were selected,and they were divided into routine group and neuroprotective agent group according to the principle of random and double-blind,with 80 cases in each group.The conventional group was treated with plasmin thrombolysis,and the neuroprotective agent group was treated with edaravone dexcanol injection on the basis of conventional treatment.After 14 days of continuous medication,the clinical efficacy,neurological deficit,life ability score and incidence of adverse reactions were compared between the two groups;at the same time,the hemodynamic indexes and fibrinogen content were compared between the two groups.Results The total clinical effective rate of the neuroprotective agent group(93.75%,75/80)was higher than that of the routine group(78.75%,63/80),P<0.05.After treatment,the National Institues of Health stroke scale(NIHSS)scores of the two groups were lower than those before treatment,and the Activity of Daily Living Scale(ADL)scores were higher than those before treatment.The improvement effect of NIHSS and ADL scores in the neuroprotective agent group was better than that in the routine group,and the difference was statistically significant(P<0.05).The hematocrit,whole blood high shear viscosity,plasma viscosity and fibrinogen content in the neuroprotective agent group were lower than those in the routine group(all P<0.05).The incidence of adverse reactions in the neuroprotective agent group(7.50%,6/80)was lower than that in the routine group(18.75%,15/80),P<0.05.Conclusions Edaravone in the treatment of acute cerebral infarction can effectively improve the neurological deficit,quality of life and hemodynamic indexes of patients,with definite clinical effect and high safety.
作者
张迎新
焦雨欢
王振焕
Zhang Yingxin;Jiao Yuhuan;Wang Zhenhuan(Department of NeurologyⅣ,Nanyang First People’s Hospital,Nanyang 473000,China)
出处
《中国实用医刊》
2022年第14期98-101,共4页
Chinese Journal of Practical Medicine
